TransMedics director exercises options, sells 3,571 shares

TransMedics Group, Inc. director David Weill reported an option exercise and related share sale.

(High)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TransMedics Group, Inc. director David Weill reported an option exercise and related share sale. On March 4, 2026, he exercised a stock option for 3,571 shares of common stock at $14.20 per share after the derivative security was fully vested. He then sold 3,571 shares of common stock in an open-market transaction at a price of $146.82 per share. After these transactions, he directly owned 12,134 shares of common stock and held 1,429 stock option shares.

Insider Trade Summary

Exercise and Sale: 3,571 shares ($474K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Weill David

Role Director

Sold 3,571 shs ($524K)

Approx. gross sale proceeds $524K

Approx. exercise cost $51K

Approx. pre-tax spread $474K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,571	$0.00	$0.00
Exercise	Common Stock	3,571	$14.20	$51K
Sale	Common Stock	3,571	$146.82	$524K

Holdings After Transaction: Stock Option (Right to Buy) — 1,429 contracts (Direct); Common Stock — 12,134 shares (Direct)

Footnotes (1)

F1. The option is fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TransMedics (TMDX) director David Weill report in this Form 4?

David Weill reported exercising a stock option and selling shares. He acquired 3,571 shares of TransMedics common stock through an option exercise and sold 3,571 shares in an open-market transaction on March 4, 2026.

How many TransMedics (TMDX) shares did David Weill sell and at what price?

David Weill sold 3,571 shares of TransMedics common stock. The reported sale price was $146.82 per share in an open-market or private transaction classified under transaction code "S" on March 4, 2026.

What stock option activity did David Weill report for TransMedics (TMDX)?

He reported exercising a fully vested stock option for 3,571 shares. The shares were acquired at an exercise price of $14.20 per share through a derivative exercise/conversion classified under transaction code "M" on March 4, 2026.

How many TransMedics (TMDX) shares does David Weill own after these transactions?

Following the reported transactions, David Weill directly owned 12,134 shares of TransMedics common stock. He also held 1,429 shares underlying stock options after exercising part of his previously granted option award.

Was the TransMedics (TMDX) stock option held by David Weill vested?

Yes. A footnote states that the option is fully vested. This means the entire option grant was exercisable when he chose to convert 3,571 option shares into TransMedics common stock on March 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/06/2026 - 06:09 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weill David

(Last)

(First)

(Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER

01810

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/04/2026		M		3,571	A	$14.2	15,705	D
Common Stock	03/04/2026		S		3,571	D	$146.82	12,134	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.2	03/04/2026		M			3,571	⁽¹⁾	06/04/2030	Common Stock	3,571	$0.00	1,429	D

Explanation of Responses:

1. The option is fully vested.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR